Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Ibrutinib (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms iLOC
- 06 Dec 2016 Interim results (n=18) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 06 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 22 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.